Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6635280 | SANTARUS INC | Extending the duration of drug release within the stomach during the fed mode |
Sep, 2016
(7 years ago) | |
US6340475 | SANTARUS INC | Extending the duration of drug release within the stomach during the fed mode |
Sep, 2016
(7 years ago) | |
US6488962 | SANTARUS INC | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
Jun, 2020
(3 years ago) | |
US6723340 | SANTARUS INC | Optimal polymer mixtures for gastric retentive tablets |
Oct, 2021
(2 years ago) | |
US7780987 | SANTARUS INC | Controlled release dosage forms |
Mar, 2025
(10 months from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8323692 | SANTARUS INC | Controlled release dosage forms |
Mar, 2023
(1 year, 29 days ago) |
Drugs and Companies using METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 03 June, 2005
Treatment: Indication of type ii diabetes
Dosage: TABLET, EXTENDED RELEASE;ORAL